Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANOPTIMOX: FOLFIRINOX vs. FOLFIRINOX with LV5FU2 Maintenance vs. FIRGEM in Metastatic Pancreatic Cancer
NCT02352337Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, folinic acid, irinotecan, oxaliplatin and gemcitabine in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After Randomization. Started Jan 2015; status: completed.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatingemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02352337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352337.